In a phase II study, MEF2B-mutant patients with relapsed/refractory DLBCL had a higher response rate to panobinostat, an HDAC inhibitor, than those without MEF2B mutations [60]. The gene discussed is HDAC9; the disease is diffuse large B-cell lymphoma.